These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17366681)

  • 41. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial.
    Socinski MA; Raju RN; Neubauer M; Smith DA; Richards DA; Savin M; Ruxer RL; Reynolds CH; Zhan F; Bromund JL; Chen R; Obasaju C
    J Thorac Oncol; 2008 Nov; 3(11):1308-16. PubMed ID: 18978567
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
    de Marinis F; Ricciardi S
    Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
    Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Subacute cutaneous lupus erythematosus associated with pemetrexed plus Carboplatin chemotherapy.
    González García A; Sifuentes Giraldo WA; Grillo Fernández E; Zea Mendoza A
    J Clin Rheumatol; 2014 Dec; 20(8):449-50. PubMed ID: 25417687
    [No Abstract]   [Full Text] [Related]  

  • 48. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiation recall dermatitis with pemetrexed.
    Hureaux J; Le Guen Y; Tuchais C; Savary L; Urban T
    Lung Cancer; 2005 Nov; 50(2):255-8. PubMed ID: 16111784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
    Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
    Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B
    Baldi M; Behera D; Kaur J; Kapoor R; Singh N
    Clin Lung Cancer; 2017 Jul; 18(4):432-435. PubMed ID: 28073680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
    Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
    J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study.
    Llombart-Cussac A; Theodoulou M; Rowland K; Clark RS; Nakamura T; Carrasco E; Cruciani G
    Clin Breast Cancer; 2006 Dec; 7(5):380-5. PubMed ID: 17239262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
    Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
    Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pemetrexed-induced hyperpigmentation of the skin.
    Schallier D; Decoster L; de Greve J
    Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
    Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
    J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.